EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> DBV Technologies filed a biologics license application for Viaskin Peanut. The submission features data intended to address the FDA’s issues with the original filing. Statement  

> A phase 2b/3 trial of TopiVert Pharma’s treatment for dry eye disease missed its primary endpoints. TopiVert plans to run another study of the drug. Release 

> ObsEva secured a $75 million credit facility with Oxford Finance. The Swiss company will use the money to fund phase 3 trials. Statement 

Webinar

Digitize remote site monitoring with Box

Box will discuss how your life sciences organization can continue to propel therapies & devices through the value chain with faster and even more secure site monitoring and auditing.

> MorphoSys signaled its intention to file for approval of tafasitamab in Europe. The plan is to complete the submission around the middle of next year. Release

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.